Epidermal growth factor receptor‐tyrosine kinase inhibitor therapy is especially beneficial to patients with exon 19 deletion compared with exon 21 L858R mutation in non‐small‐cell lung cancer: Systematic review and meta analysis

@inproceedings{Liu2016EpidermalGF,
  title={Epidermal growth factor receptor‐tyrosine kinase inhibitor therapy is especially beneficial to patients with exon 19 deletion compared with exon 21 L858R mutation in non‐small‐cell lung cancer: Systematic review and meta analysis},
  author={Yinghui Liu and Zuen Ren and Jinghui Wang and Shucai Zhang},
  booktitle={Thoracic cancer},
  year={2016}
}
BACKGROUND The correlation between epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and EGFR sensitive mutation subtypes in advanced or metastatic non-small cell lung cancer (NSCLC) remains uncertain. We performed this meta-analysis to determine different clinical outcomes between patients with exon 19 deletion accepting EGFR-TKI therapy compared with those with exon 21 L858R mutation. METHODS PubMed and Web of Science were analyzed for eligible trials. Raw data were… CONTINUE READING
Highly Cited
This paper has 112 citations. REVIEW CITATIONS
7 Citations
40 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

112 Citations

010020020172018
Citations per Year
Semantic Scholar estimates that this publication has 112 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
Showing 1-10 of 40 references

Thoracic Cancer 7 (2016

  • Y. Liu
  • 2016

; 140 : 1911 )

  • C Zhou, YL Wu, G Chen
  • J Cancer Res Clin Oncol
  • 2014

Cancer statistics ,

  • JG Paez, PA Jänne, JC Lee
  • 2014

Similar Papers

Loading similar papers…